TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks

Group 1 - The article expresses consistent optimism about TriSalus Life Sciences (TLSI) and outlines the expected course for the company [1] - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies, emphasizing the importance of understanding the science behind investments [1] Group 2 - There are no disclosed stock or derivative positions in any mentioned companies, indicating an unbiased perspective [2] - The article reflects the author's personal opinions and is not influenced by compensation from any company [2]